Rothberg MB, Haessler SD, Brown RB. Complications of viral influenza. Am j med. 2008; 121 (4): 258–264.
Buchy P, Selim B. Who and when to vaccinate against influenza. Inter J Infect Dis. 2020; 93: 375–387.
Manzoli L, Schioppa F, Boccia A, et al. The efficacy of influenza vaccine for healthy children. A meta-analysis evaluating potential sources of variation in efficacy estimates including study quality. Pediatr Infect Dis J. 2007; 26 (2): 97–106. doi: 10.1097/01.inf.0000253053.01151.bd
Jefferson T, Rivetti A, Harnden A, et al. Vaccines for preventing influenza in health children. Cochrane Database Syst Rev. 2008; 2.
Negri E, Colombo C, Giordano L, et al. Influenza vaccine in healthy children: a meta-analysis. Vaccine. 2005; 23 (22): 2851–2861. doi: 10.1016/j.vaccine.2004.11.053
Villari P, Manzoli L, Boccia A. Methodological quality of studies and patient age as major sources of variation in efficacy estimates of influenza vaccination in healthy adults: a meta-analysis. Vaccine. 2004; 22 (25–26): 3475–3486. doi: 10.1016/j.vaccine.2004.01.068
Beyer WEP. Heterogeneity of case definitions used in vaccine effectiveness studies—and its impact on meta-analysis. Vaccine. 2006; 24 (44–46): 6602–6604. doi: 10.1016/j.vaccine.2006.05.038
Demicheli V, Jefferson T, Ferroni E, et al. Vaccines for preventing influenza in healthy adults. Cochrane Database Syst Rev. 2018; 2.
Govaert TM, Thijs CT, Masurel N, et al. The efficacy of influenza vaccination in elderly individuals. A randomized double-blind placebo-controlled trial. JAMA. 1994; 272 (21): 1661–1665. doi: 10.1001/jama.1994.03520210045030
Nichol KL, Wuorenma J, Von Sternberg T. Benefits of influenza vaccination for low-, intermediate-, and high-risk senior citizens. Arch Internal Med. 1998; 158 (16): 1769–1776.
Sanyal M, Holmes TH, Maecker HT, et al. Diminished B-cell response after repeat influenza vaccination. J Infect Dis. 2019; 219 (10): 1586–1595.
Khurana S, Hahn M, Coyle EM, et al. Repeat vaccination reduces antibody affinity maturation across different influenza vaccine platforms in humans. Nat Commun. 2019; 10 (1): 1–15.
Ramsay LC, Buchan SA, Stirling RG, et al. The impact of repeated vaccination on influenza vaccine effectiveness: a systematic review and meta-analysis. BMC Med. 2019; 17 (1): 1–16.
Bartoszko JJ, McNamara IF, Aras OA, et al. Does consecutive influenza vaccination reduce protection against influenza: a systematic review and meta-analysis. Vaccine. 2018; 36 (24): 3434–3444.
Soema PC, Kompier R, Amorij JP, et al. Current and next generation influenza vaccines: formulation and production strategies. Eur J Pharm Biopharm. 2015; 94: 251–263.
Krammer F, Fouchier RA, Eichelberger MC, et al. Naction! How can neuraminidase-based immunity contribute to better influenza virus vaccines? MBio. 2018; 9 (2): e02332–17.
Sangster S, Nguyen MYPQ, Topham DJ. Role of memory B cells in hemagglutinin-specific antibody production following human influenza a virus infection. Pathogens. 2019; 8 (4): 167.
Hannoun C, Megas F, Piercy J. Immunogenicity and protective efficacy of influenza vaccination. Virus res. 2004; 103 (1–2): 133–138.
Gelman A, Hill J. Data analysis using regression and multilevel/hierarchical models. Cambridge university press; 2006.
Khurana S, Verma N, Talaat KR, et al. Immune response following H1N1pdm09 vaccination: differences in antibody repertoire and avidity in young adults and elderly populations stratified by age and gender. J Infect Dis. 2012; 205 (4): 610–620. doi: 10.1093/infdis/jir791
Verma N, Dimitrova M, Carter DM, et al. Influenza virus H1N1pdm09 infections in the young and old: evidence of greater antibody diversity and affinity for the hemagglutinin globular head domain (HA1 domain) in the elderly than in young adults and children. J Virol. 2012; 86 (10): 5515–5522. doi: 10.1128/JVI.07085-11
Gouma S, Kim K, Weirick ME, et al. Middle-aged individuals may be in a perpetual state of H3N2 influenza virus susceptibility. Nat Commun. 2020; 11 (1): 4566. doi: 10.1038/s41467-020-18465-x
Monto AS, Fukuda K. Lessons from influenza pandemics of the last 100 years. Clinl Infect Dis. 2020; 70 (5): 951–957.
Wrammert J, Smith K, Miller J, et al. Rapid cloning of high-affinity human monoclonal antibodies against influenza virus. Nature. 2008; 453 (7195): 667–671. doi: 10.1038/nature06890
Davis CW, Jackson KJ, McCausland MM, et al. Influenza vaccine–induced human bone marrow plasma cells decline within a year after vaccination. Science. 2020; 370 (6513): 237–241.
Nutt SL, Hodgkin PD, Tarlinton DM, et al. The generation of antibody-secreting plasma cells. Nat Rev Immunol. 2015; 15: 160–171. doi: 10.1038/nri3795
Shlomchik MJ, Weisel F. Germinal center selection and the development of memory B and plasma cells. Immunol Rev. 2012; 247 (1): 52–63. doi: 10.1111/j.1600-065X.2012.01124.x
Radbruch A, Muehlinghaus G, Luger EO, et al. Competence and competition: the challenge of becoming a long-lived plasma cell. Nat Rev Immunol. 2006; 6 (10): 741–750. doi: 10.1038/nri1886
MacLennan IC, Toellner K-M, Cunningham AF, et al. Extrafollicular antibody responses. Immunol Rev. 2003; 194 (1): 8–18. doi: 10.1034/j.1600-065X.2003.00058.x
Madsen A, Cox RJ. Prospects and challenges in the development of universal influenza vaccines. Vaccines. 2020; 8 (3): 361.
Estrada LD, Schultz-Cherry S. Development of a universal influenza vaccine. J Immunol. 2019; 202 (2): 392–398. doi: 10.4049/jimmunol.1801054
Paules CI, Marston HD, Eisinger RW, et al. The pathway to a universal influenza vaccine. Immunity. 2017; 47 (4): 599–603. doi: 10.1016/j.immuni.2017.09.007
Pica N, Palese P. Toward a universal influenza virus vaccine: prospects and challenges. Annu Rev Med. 2013; 64 (1): 189–202. doi: 10.1146/annurev-med-120611-145115
Fiers W, De Filette M, El Bakkouri K, et al. M2e-based universal influenza a vaccine. Vaccine. 2009; 27 (45): 6280–6283. doi: 10.1016/j.vaccine.2009.07.007
Wei CJ, Crank MC, Shiver J, et al. Next-generation influenza vaccines: opportunities and challenges. Nat Rev Drug Discov. 2020; 19 (4): 239–252.
Yuan L, Welsh JP, Swartz JR. Production and stabilization of the trimeric influenza hemagglutinin stem domain for potentially broadly protective influenza vaccines. Proc Nat Acad Sci. 2014; 111 (1): 125–130.
Eichelberger MC, Monto AS. Neuraminidase, the forgotten surface antigen, emerges as an influenza vaccine target for broadened protection. J Infect Dis. 2019; 219 (Supplement_1): S75–S80.
Mezhenskaya D, Isakova-Sivak I, Rudenko L. M2e-based universal influenza vaccines: a historical overview and new approaches to development. J Biomed Sci. 2019; 26 (1): 1–15.
Hoskins TW, Davies J, Allchin A, et al. Controlled trial of inactivated influenza vaccine containing the A/Hong kong strain during an outbreak of influenza due to the A/England/42/72 strain. Lancet. 1973; 302 (7821): 116–120.
Hoskins TW, JoanR Davies AJS, Allchin A, et al. Influenza at Christ’s hospital: March, 1974. Lancet. 1976; 307 (7951): 105–108.
Hoskins TW, Davies J, Smith AJ, et al. Assessment of inactivated influenza-A vaccine after three outbreaks of influenza a at Christ’s hospital. Lancet. 1979; 313 (8106): 33–35.
Keitel WA, Cate TR, Couch RB, et al. Efficacy of repeated annual immunization with inactivated influenza virus vaccines over a five year period. Vaccine. 1997; 15 (10): 1114–1122.
Skowronski DM, Chambers C, De Serres G, et al. Serial vaccination and the antigenic distance hypothesis: effects on influenza vaccine effectiveness during a (H3N2) epidemics in Canada, 2010–2011 to 2014–2015. J Infect Dis. 2017; 215 (7): 1059–1099.
Smith DJ, Forrest S, Ackley DH, et al. Variable efficacy of repeated annual influenza vaccination. Proc Nat Acad Sci. 1999; 96 (24): 14001–14006.
Plant EP, Fredell LJ, Hatcher BA, et al. Different repeat annual influenza vaccinations improve the antibody response to drifted influenza strains. Sci Rep. 2017; 7 (1): 1–12.
Carrat F, Flahault A. Influenza vaccine: the challenge of antigenic drift. Vaccine. 2007 Sep28; 25 (39–40): 6852–6862. doi: 10.1016/j.vaccine.2007.07.027
